Characteristics of Included Studies

MethodsParticipantsOutcomesInterventionsNotes
GOODMAN1990A
Study Type: RCT

Study Description: Allocation: random (no details)
Blindness: Double blind

Duration (days):

Followup: 8 weeks

Setting: Outpatients

Notes: Country of study: US; Analysis: ITT

Info on Screening Process: Not reported		N= 40

Age: Mean 38

Sex: 19 males 21 females

Diagnosis:
  • 100% OCD by DSM-III-R
Exclusions: OCD duration <1 year, CGI-global severity >=moderate; primary depression; MDD primary diagnosis

Notes: Patients with current major depression: Fluvoxamine n=14, Desipramine n=13; chronic tics history n=6; patients attended weekly individual psychotherapy (comprised supportive therapy, psychoeducation, relaxation techniques); mean OCD duration 18 years		Data Used
  • Leaving study early due to adverse events
  • Leaving study early
  • Hamilton Rating Scale for Depression
  • Yale-Brown Obsessive-Compulsive Scale: total
Group 1 N= 19
  • Desipramine - 50mg for first 3 days, increased to 150mg by 2nd week, and upto 300mg based on clinical response; mean final dose 223mg/d (+-48)
Group 2 N= 21
  • Fluvoxamine - 50mg for first 3 days, increased to 150mg by 2nd week, and upto 300mg based on clinical response; mean final dose 214mg/d (+-55)
HOEHNSARIC2000
Study Type: RCT

Study Description: Randomization using a computer-generated randomization scheme

Blindness: Double blind

Duration (days):

Followup: 12 weeks

Setting: Not reported

Notes: Country of study: US; Analysis: ITT; study conducted at 16 sites

Info on Screening Process: Not reported		N= 116

Age: Mean 38

Sex: 66 males 48 females

Diagnosis:
  • 100% OCD by DSM-III-R
  • 100% MDD by DSM-III-R
Exclusions: Y-BOCS<20, HRSD-24<18, HRSD-item 1<2, CGI for OCD & MDD<4

Notes: OCD duration: 213 mo; MDD duration 24 mo; Y-BOCS baseline 26; HRSD-24 baseline: 27.5		Data Used
  • Responder (OCD/BDD)
  • Responder (MDD)
  • Remission (MDD)
  • Leaving study early due to adverse events
  • Leaving study early
  • Adverse events
  • Hamilton Rating Scale for Depression
  • NIMH-OC
  • Yale-Brown Obsessive-Compulsive Scale: total
Group 1 N= 80
  • Sertraline - flexible dosage (based on response and side-effects): 50mg/d first 2 weeks, 100mg/d by week 4, 150mg/d at week 4, 200mg/d at week 5; mean final dose 160.1mg/d+-50
Group 2 N= 86
  • Desipramine - flexible dosage (based on response and side-effects): 50mg/d titrated upto 300mg/d; mean final dose 193.5mg/d+-90
Response: for OCD: Y-BOCS>=40% reduction, for MDD: HRSD>=50% reduction; MDD remission: HRSD<=17
JENIKE1997
Study Type: RCT

Study Description: Allocation: random (no details)

Blindness: No mention

Duration (days):

Followup: 10 weeks

Setting: Outpatient

Notes: Country of study: US; Analysis: ITT

Info on Screening Process: Not reported		N= 64

Age: Mean 35

Sex: 36 males 28 females

Diagnosis:
  • OCD by DSM-III-R
Exclusions: Aged<18 years, OCD duration<1 year, NIMH-OC<7, DSM Major depression, HRSD>17

Notes: OCD duration not reported; baseline Y-BOCS 19; baseline NIMH-OC 7.7		Data Used
  • Clinical Global Impressions
  • OCD Scale (CPRS)
  • Leaving study early
  • NIMH-OC
  • Yale-Brown Obsessive-Compulsive Scale: total
Group 1 N= 23
  • Fluoxetine - Subjects titrated to 80mg/day by week 3; mean maxiumum dose 77.9mg/day
Group 2 N= 20
  • Phenelzine - Subjects titrated to 60mg/day by week 3; all patients achieved maximum dose
Group 3 N= 21
  • Placebo
PATO1991
Study Type: Cross-over

Study Description: Cross-over after 6 weeks of active drug treatment.

Blindness: Double blind

Duration (days):

Notes: Country of study: US
Mean (SD) doses were 225(49) mg/day for clomipramine and 58 (7) mg/day for buspirone.		N= 20

Age: Mean 35

Sex: no information

Diagnosis:
  • OCD by DSM-III-R
Notes: Patients had experienced obsessive-compulsive symptoms for a minimum of one year. A minimum rating of 4 on the NIMH global OC scale was required for inclusion in the study.		Data Used
  • NIMH-OC
  • Hamilton Rating Scale for Depression
  • Yale-Brown Obsessive-Compulsive Scale: total
  • Leaving study early due to adverse events
  • Leaving study early
Group 1 N= 9
  • Clomipramine - Each patient's dose was increased to the maximum that could be tolerated, up to 250mg/day. Patients achieved the maximum doses by day 14 and were maintained on these for the remaining 4 weeks of of the 6-week phase.
Group 2 N= 9
  • Buspirone - Each patient's dose was increased to the maximum that coould be tolerated, up to 60mg/day. Patients achieved the maximum doses by day 14 and were maintained on these for the remaining 4 weeks of the 6-week phase.
VALLEJO1992
Study Type: RCT

Blindness: Double blind Duration (days):

Followup: 12 weeks

Setting: Outpatient

Notes: Country of study: UK; Analysis: completer

Info on Screening Process: 42, 12 excluded due to pregnancy, under age, psychopathy, schizophrenia, hysteria, anankastic depression, refusal to give signed informed consent		N= 30

Age: Mean 32

Sex: 12 males 14 females

Diagnosis:
  • OCD by DSM-III
  • 31% MDD
Exclusions: Aged <18 and >65 years, OCD duration <2 years, primary depression, other psychoses, physical illness, organic brain pathology, pregnant or breast-feeding

Notes: OCD duration 17 years		Data Used
  • Leaving study early due to adverse events
  • Leaving study early
  • Hamilton Rating Scale for Depression
  • Hamilton Rating Scale for Anxiety
  • Maudsley Obsessive-Compulsive Inventory
Group 1 N= 14
  • Phenelzine - 45mg/d weeks 1&2, 60mg/d weeks 3 & 4, 75mg/d weeks 5-12
Group 2 N= 16
  • Clomipramine - 75mg/d weeks 1&2, 150mg/d weeks 3 & 4, 225mg/d weeks 5-12
VOLAVKA1985
Study Type: RCT

Study Description: Allocation: random (computer-generated random numbers in blocks of six patients)

Blindness: Double blind

Duration (days):

Followup: 12

Setting: Outpatient

Notes: Country of study: US; Analysis:

Info on Screening Process: Not reported		N= 23

Age: Mean 30 Range 19-54

Sex: 11 males 12 females

Diagnosis:
  • OCD
Exclusions: Aged <18 and >65 years, OCD duration <1 year, primary depression, significant medical disease, schizophrenia, pregnancy, concomittant use of other psychotropic drugs, alcohol or drug abuse

Notes: Did not use standardised diagnostic tool		Data Used
  • Global Evaluation of Efficacy
  • Leaving study early due to adverse events
  • Leaving study early
  • Self-Rating Obsessional Neurotic Scale
  • Hamilton Rating Scale for Depression
  • Self-Rating Obsessive-Compulsive Personality
Group 1 N= 11
  • Clomipramine - Gradual increase (by 50mg/d each week) to 300mg/d, maximum dose was reached by week 5
Group 2 N= 12
  • Imipramine - Gradual increase (by 50mg/d each week) to 300mg/d, maximum dose was reached by week 5

From: Appendix 16, Characteristics of reviewed studies

Cover of Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder.
NICE Clinical Guidelines, No. 31.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society (UK); 2006.
© NCCMH. All rights reserved.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.